ReviewJournal of mammary gland biology and neoplasia2011
TGFBR1 signaling and breast cancer.
Review in Journal of mammary gland biology and neoplasia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Association between Int7G24A rs334354 polymorphism and cancer risk: a meta-analysis of case-control studies.Scientific reports · 2015Pooled it
- Pan-cancer prognostic value of TGFBR1: Bioinformatics and experimental validation with a focus on gastric cancer.Oncology letters · 2026Article
- Transforming growth factor-β and integrins: key players in EMT and breast cancer progression.Cancer cell international · 2026Review
- CCDC110 promotes the progression of hepatocellular carcinoma by activating the TGF-β/SMAD signaling pathway through targeted regulation of TGFBR1.Cancer cell international · 2025Article
- DataXflow: Synergizing data-driven modeling with best parameter fit and optimal control - An efficient data analysis for cancer research.Computational and structural biotechnology journal · 2024Article
- Identification of cancer driver genes based on hierarchical weak consensus model.Health information science and systems · 2024Article
- Construction and validation of a machine learning-based immune-related prognostic model for glioma.Journal of cancer research and clinical oncology · 2024Article
- XPO1 serves as a prognostic marker involving AKT/MAPK/TGFBR1 pathway in OSCC.Cancer medicine · 2024Article
- Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.Breast cancer research : BCR · 2024Article
- Autotaxin Inhibition with IOA-289 Decreases Breast Tumor Growth in Mice Whereas Knockout of Autotaxin in Adipocytes Does Not.Cancers · 2023Article
- M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway.Cell death and differentiation · 2023Article
- Aberrantly Expressed MicroRNAs in Cancer-Associated Fibroblasts and Their Target Oncogenic Signatures in Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects.NPJ breast cancer · 2022Review
- Keratin 80 Promotes Migration and Invasion of Non-Small Cell Lung Cancer Cells by Regulating the TGF-Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Transforming growth factor-β in tumour development.Frontiers in molecular biosciences · 2022Review
- TRIM44 Promotes Endometrial Carcinoma Progression by Activating the FRS2 Signalling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- LRP-1 Matricellular Receptor Involvement in Triple Negative Breast Cancer Tumor Angiogenesis.Biomedicines · 2021Article
- Role and clinical significance of TGF‑β1 and TGF‑βR1 in malignant tumors (Review).International journal of molecular medicine · 2021Review
- Identification of miR-135b as a novel regulator of TGFβ pathway in gastric cancer.Journal of physiology and biochemistry · 2020Article
- Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Over the past decade mutations discovered in genes such as BRCA1, BRCA2, TP53 and PTEN, have emerged as high-penetrance susceptibility genes and are clinically relevant for determination of breast cancer risk. Genetic counseling and subsequent screening for mutations and gene rearrangement has improved patient outcome through early detection and prophylactic interventions in patients with familial breast cancer syndromes. However, these high-penetrance genes only account for a small fraction of the hereditary linked breast cancers. It is currently believed that low-penetrance susceptibility alleles and/or environmental factors may play an important role in the remaining cases. TGFBR1*6A (*6A) is a common hypomorphic variant of the type I TGF-β receptor gene (TGFBR1) that has been associated with risk for several forms of cancer, in particular breast cancer. Several epidemiological studies have suggested that patients who carry the *6A allele have an increased risk of breast cancer. Furthermore, functional analysis suggests that this mutation alters TGF-β signaling and promotes tumorigenesis. Although a decade of research has provided basic information in regards to the prevalence of this mutation in several cancer types and populations the molecular underpinning of its functional effects are poorly understood. A better understanding of the molecular mechanism of TGFBR1 signaling in breast cancer may have an impact on breast cancer risk assessment and breast cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.